Author:
de Weger Vincent A.,de Jonge Maja,Langenberg Marlies H. G.,Schellens Jan H. M.,Lolkema Martijn,Varga Andrea,Demers Brigitte,Thomas Koruth,Hsu Karl,Tuffal Gilles,Goodstal Samantha,Macé Sandrine,Deutsch Eric
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Levine, A. J. & Oren, M. The first 30 years ofp53: growing ever more complex. Nat. Rev. Cancer 9, 749–758 (2005).
2. Olivier, M., Hollstein, M. & Hainaut, P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2, a001008 (2010).
3. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004).
4. Wang, S. et al. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 74, 1–11 (2004).
5. de Jonge, M. et al. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. Eur. J. Cancer 76, 144–151 (2017).
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献